Physician profile
Michelle Double
NPI 1902393002
$3,598.20
in general payments reported to CMS, 2019-2025
24 companies · $745 in 2025
The $745 reported for 2025 was more than what 82% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $447 · 2022: $369 · 2023: $1,230 · 2024: $807 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,781.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $507.79 | 2023-2025 | |
| Novo Nordisk INC | $460.82 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $398.04 | 2023-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.55 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $275.50 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $259.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $198.13 | 2023-2025 | Veozah, Myrbetriq |
| Stryker Corporation | $160.14 | 2023 | Mako |
| Pfizer INC. | $147.54 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.21 | 2022-2023 | |
| Esperion Therapeutics, INC. | $108.48 | 2021-2024 | Nexletol |
| Abbott Laboratories | $107.65 | 2024-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $101.65 | 2021-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $98.29 | 2022-2024 | Quviviq |
| Glaxosmithkline, LLC. | $80.63 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $72.64 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $56.07 | 2021-2024 | Evusheld, Farxiga |
| Amarin Pharma, INC. | $48.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.55 | 2021 | |
| Boston Scientific Corporation | $23.25 | 2024 | Watchman Flx |
| Biomarin Pharmaceutical INC. | $22.14 | 2024 | Voxzogo 1.2mg |
| Medtronic, INC. | $22.12 | 2024 | Intellis Adaptivestim |
| Axsome Therapeutics, INC. | $19.36 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $13.27 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Double listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.